|
|
|
|
|
|
|
09.06.25 - 13:03
|
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 (GlobeNewswire EN)
|
|
|
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 2:00 PM ET. To register, click here....
|
|
|
|
|
|
|
|
|
|
|
23.04.25 - 14:03
|
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 (GlobeNewswire EN)
|
|
|
SAN MATEO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that three poster presentations featuring additional analyses from the Phase 2b FASCINATE-2 study of denifanstat in MASH will be presented at the European Association for the Study of Liver (EASL) Congress 2025 being held May 7-10, 2025 in Amsterdam, Netherlands....
|
|
|
|
|
|
|
|
|
|
|
|
|
06.12.24 - 08:26
|
U.S. Doordash, Sagimet Biosciences, Ulta Beauty (Reuters EN)
|
|
|
U.S. RESEARCH ROUNDUP- Doordash, Sagimet Biosciences, Ulta Beauty Dec 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Doordash, Sagimet Biosciences and Ulta Beauty, on Friday. HIGHLIGHTS * Doordash DASH.O : RBC raises target price to $215 from $175 * Graftech International Ltd EAF.N : JP Morgan raises to neutral from underweight * Sagimet Biosciences Inc SGMT.O : Oppenheimer initiates coverage with outperform ratin...
|
|
|
|
|
|
|
29.10.24 - 12:03
|
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 (GlobeNewswire EN)
|
|
|
SAN MATEO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the successful completion of end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), supporting the advancement of denifanstat into Phase 3 in metabolic-dysfunction associated steatohepatitis (MASH). The planned program will include two Phase 3 trials: FASCINATE-3, evaluating patients with F2/F3 (non-cirrhotic) MASH, and FASCINIT, evaluating patients with suspected or confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH. The Phase 3 program is expected to initiate by the end of 2024....
|
|
|
16.10.24 - 13:04
|
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024 (GlobeNewswire EN)
|
|
|
SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor, denifanstat, and preclinical data demonstrating atherosclerosis improvement with FASN inhibitor treatment, will be highlighted in three presentations at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2024, taking place November 15-19, 2024 in San Diego, California....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
